REPLIGEN CORP Interest Payable, Current
REPLIGEN CORP (RGEN) had Interest Payable, Current of $806.00 thousand as of 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2017-11-09
- 2017-09-30: Interest Payable, Current $806.00K.
- 2017-06-30: Interest Payable, Current $204.00K.
- 2017-03-31: Interest Payable, Current $815.00K.
- 2016-12-31: Interest Payable, Current $204.00K.
| Period end | Interest Payable, Current |
|---|---|
| 2017-09-30 | $806.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $204.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $815.00K 10-Q · filed 2017-05-04 |
| 2016-12-31 | $204.00K 10-Q · filed 2017-11-09 |
| 2016-09-30 | $862.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $251.00K 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |